Celcuity (CELC, Financial), a cutting-edge biotechnology company, has had its stock position reiterated as a "Buy" by Needham, one of the prominent firms in financial analysis. This rating, provided by analyst Gil Blum, underscores the company's stable outlook in the market as of the latest assessment on May 15, 2025.
The analyst has maintained a price target of USD 29.00 for CELC, confirming their previous expectations for the stock's performance. This price target remains unchanged from the prior assessment, reflecting consistent confidence in the company's potential within the biotech sector.
The reaffirmation of the "Buy" rating and a steady price target by Needham suggest a positive sentiment towards CELC's future growth and strategic direction, aligning with previous forecasts.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Celcuity Inc (CELC, Financial) is $28.50 with a high estimate of $33.00 and a low estimate of $27.00. The average target implies an upside of 162.43% from the current price of $10.86. More detailed estimate data can be found on the Celcuity Inc (CELC) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Celcuity Inc's (CELC, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
